{ "items": [ "\n\n
\n \n\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n13 January 2023
\n \n \n \nResearchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.
\n \n\n \n \n\n \n\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n19 December 2022
\n \n \n \nMore than 40,000 doses of Oxford\u2019s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n7 December 2022
\n \n \n \nDaniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n13 September 2022
\n \n \n \nA severe flu outbreak or new coronavirus variant could prove catastrophic for a health service already on its knees
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n6 July 2022
\n \n \n \nUp to $30 million in funding has been announced by the Coalition for Epidemic Preparedness Innovations (CEPI) to bring a new nanoparticle vaccine offering protection against a range of coronaviruses to clinical trial.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n\n \n\n\n
\n \n\n \n1 July 2022
\n \n \n \nProfessor Sir Andrew Pollard, BSc MA MBBS MRCP(UK) FRCPCH PhD DIC FHEA FIDSA FMedSci, is Professor of Paediatric Infection and Immunity at the University of Oxford, Honorary Consultant Paediatrician at Oxford Children\u2019s Hospital and Vice Master of St Cross College, Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n26 May 2022
\n \n \n \nResearchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 \u2013 with a focus on assessing different options for a third dose booster vaccination.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n16 May 2022
\n \n \n \nCOVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.
\n \n\n \n \n10 May 2022
\n \n \n \nThe University of Oxford in collaboration with the University of Maryland School of Medicine (UMSoM) has begun recruiting for a Phase I/II trial of a new paratyphoid vaccine in human volunteers in Oxford.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n8 November 2021
\n \n \n \nThe University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n\n \n\n\n
\n \n\n \n24 September 2021
\n \n \n \nCongratulations to Professor Sue Ann Costa Clemens for her Honarary CBE award for her positive contribution towards public health. Here at the Oxford Vaccine Group and the Paediatrics department, we are extremely proud of what Sue and her team have achieved.
\n \n\n \n \n20 August 2021
\n \n \n \nThere\u2019s no evidence yet that top-up shots are needed, so let\u2019s help those around the world who urgently need the vaccine - writes Andrew Pollard in an opinion piece for The Guardian.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n\n \n\n\n
\n \n\n \n9 August 2021
\n \n \n \nDr Samantha Vanderslott (Oxford Vaccine Group) and Dr Claas Kirchhelle (University College Dublin) have had their three-year project \u2018Typhoid, Cockles, and Terrorism\u2019 about the history of typhoid in Dublin successfully funded.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n30 July 2021
\n \n \n \nProfessor Sir Andrew Pollard, Director of the Oxford Vaccine Group and Professor of Paediatric Infection and Immunity, takes a moment to reflect on one billion doses of the Oxford coronavirus vaccine released worldwide.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n30 July 2021
\n \n \n \nIf the current high levels of protection against severe disease are sustained, the global public health emergency will be curtailed by the ongoing vaccine rollout - writes Andrew Pollard for The Independent.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n29 July 2021
\n \n \n \nThe University of Oxford\u2019s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca\u2019s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
\n \n\n \n \n\n \n\n \n \n \n \n Research\n \n \n\n \n\n\n
\n \n\n \n27 July 2021
\n \n \n \nResearchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.
\n \n\n \n \n\n \n\n \n \n \n \n Awards & Appointments\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n9 July 2021
\n \n \n \nResearchers behind the Oxford AstraZeneca coronavirus vaccine have been recognised for their excellence at a healthcare awards ceremony.
\n \n\n \n \n\n \n\n \n \n \n \n Publication\n \n \n\n \n\n\n
\n \n\n \n9 July 2021
\n \n \n \n'Brain Fever', a new book by internationally-renowned medical scientist Professor Richard Moxon, describes the decades of research that contribute to the development of vaccines for life-threatening illnesses such as meningitis, and how immunisation has been our greatest public health intervention.
\n \n\n \n \n\n \n\n \n \n \n \n COVID-19\n \n \n\n \n\n\n
\n \n\n \n30 June 2021
\n \n \n \nAlternating doses of the Oxford-AstraZeneca and Pfizer-BioNTech vaccines generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.
\n \n\n \n \n